Literature DB >> 7498221

Evaluation in vitro and in rats of 161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy.

M de Jong1, W A Breeman, B F Bernard, E J Rolleman, L J Hofland, T J Visser, B Setyono-Han, W H Bakker, M E van der Pluijm, E P Krenning.   

Abstract

The characteristics of terbium-161 diethylene triamine penta-acetic acid (DTPA) labelled octreotide with respect to specific binding to somatostatin (octreotide) receptors on rat brain cortex membranes, biological activity, uptake and excretion by isolated perfused rat livers and metabolism in vivo in normal and tumour-bearing rats were determined and compared to those of indium-111 DTPA-octreotide. The results of the binding studies demonstrate that 161Tb-DTPA-octreotide is a high-affinity radioligand for somatostatin receptors, with an affinity comparable to that of 111In-DTPA-octreotide. Rat growth hormone secretion inhibition experiments showed that 161Tb-DTPA-octreotide has a similar potency to 111In-DTPA-octreotide. 161Tb-DTPA-octreotide appeared to be taken up even less by the isolated perfused rat liver than 111In-DTPA-octreotide, as almost no tracer disappeared from the perfusion medium. Furthermore, hardly any radioactivity was found in the liver, and excretion into the bile was negligible. The biodistribution studies showed that for octreotide receptor-positive organs, such as pancreas and adrenals, uptake of 161Tb-DTPA-octreotide is lower then that of 111In-DTPA-octreotide. However, as the clearance from the blood of the former compound is faster than that of the latter, the tissue/blood ratio is higher in the case of 161Tb-DTPA-octreotide than with 111In-DTPA-octreotide. Furthermore, these studies demonstrated that the uptake of 161Tb-DTPA-octreotide by the renal tubular cells after glomerular filtration can be reduced by administration of lysine or sodium maleate. Increase in urine production before and during the experiment had no effect on the kidney uptake of 161Tb-DTPA-octreotide.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7498221     DOI: 10.1007/bf01254561

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  21 in total

1.  RENAL TOXICITY OF MALEIC ACID IN THE RAT: ENZYMATIC AND MORPHOLOGIC OBSERVATIONS.

Authors:  H G WORTHEN
Journal:  Lab Invest       Date:  1963-08       Impact factor: 5.662

2.  Experimental production of renal glycosuria, phosphaturia, and aminoaciduria by injection of maleic acid.

Authors:  H E HARRISON; H C HARRISON
Journal:  Science       Date:  1954-10-15       Impact factor: 47.728

3.  Prevention of renal tubule re-absorption of radiometal (indium-111) labelled Fab fragment of a monoclonal antibody in mice by systemic administration of lysine.

Authors:  M V Pimm; S J Gribben
Journal:  Eur J Nucl Med       Date:  1994-07

4.  Studies on renal tubular protein reabsorption: partial and near complete inhibition by certain amino acids.

Authors:  C E Mogensen
Journal:  Scand J Clin Lab Invest       Date:  1977-10       Impact factor: 1.713

Review 5.  Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.

Authors:  E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi
Journal:  Eur J Nucl Med       Date:  1993-08

6.  Development and use of a mathematical two-pool model of distribution and metabolism of 3,3',5-triiodothyronine in a recirculating rat liver perfusion system: albumin does not play a role in cellular transport.

Authors:  R Docter; M de Jong; H J van der Hoek; E P Krenning; G Hennemann
Journal:  Endocrinology       Date:  1990-01       Impact factor: 4.736

7.  Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.

Authors:  E P Krenning; W H Bakker; P P Kooij; W A Breeman; H Y Oei; M de Jong; J C Reubi; T J Visser; C Bruns; D J Kwekkeboom
Journal:  J Nucl Med       Date:  1992-05       Impact factor: 10.057

8.  Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype.

Authors:  Y Yamada; S Kagimoto; A Kubota; K Yasuda; K Masuda; Y Someya; Y Ihara; Q Li; H Imura; S Seino
Journal:  Biochem Biophys Res Commun       Date:  1993-09-15       Impact factor: 3.575

9.  Effect of maleate on tubular protein reabsorption in dog kidneys.

Authors:  J Hysing; J Ostensen; H Tolleshaug; F Kiil
Journal:  Ren Physiol       Date:  1988

10.  Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue.

Authors:  P J Hammond; A F Wade; M E Gwilliam; A M Peters; M J Myers; S G Gilbey; S R Bloom; J Calam
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

View more
  12 in total

Review 1.  Impact of physiochemical properties on pharmacokinetics of protein therapeutics.

Authors:  Rajan Swami; Aliasgar Shahiwala
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-04-14       Impact factor: 2.441

2.  Highlights of the annual meeting of the European Association of Nuclear Medicine: Brussels 1995. The art of imaging the body.

Authors:  F H Corstens
Journal:  Eur J Nucl Med       Date:  1996-01

Review 3.  The diagnostic utility of somatostatin receptor scintigraphy in oncology.

Authors:  R Valkema; J Steens; F J Cleton; E K Pauwels
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 4.  Octreotide scanning for carcinoid tumours.

Authors:  M Critchley
Journal:  Postgrad Med J       Date:  1997-07       Impact factor: 2.401

Review 5.  Drug therapy alternatives in the treatment of thyroid cancer.

Authors:  M J O'Doherty; A J Coakley
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

6.  Direct in vitro and in vivo comparison of (161)Tb and (177)Lu using a tumour-targeting folate conjugate.

Authors:  Cristina Müller; Josefine Reber; Stephanie Haller; Holger Dorrer; Peter Bernhardt; Konstantin Zhernosekov; Andreas Türler; Roger Schibli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10-08       Impact factor: 9.236

7.  Human somatostatin receptor mediated antiproliferative action evokes subtype selective cytotoxic and cytostatic signaling.

Authors:  C B Srikant
Journal:  Yale J Biol Med       Date:  1997 Sep-Dec

8.  Preclinical in vivo application of (152)Tb-DOTANOC: a radiolanthanide for PET imaging.

Authors:  Cristina Müller; Christiaan Vermeulen; Karl Johnston; Ulli Köster; Raffaella Schmid; Andreas Türler; Nicholas P van der Meulen
Journal:  EJNMMI Res       Date:  2016-04-23       Impact factor: 3.138

9.  Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification.

Authors:  Magdalena Malm; Nina Kronqvist; Hanna Lindberg; Lindvi Gudmundsdotter; Tarek Bass; Fredrik Y Frejd; Ingmarie Höidén-Guthenberg; Zohreh Varasteh; Anna Orlova; Vladimir Tolmachev; Stefan Ståhl; John Löfblom
Journal:  PLoS One       Date:  2013-05-10       Impact factor: 3.240

10.  Comparison between Three Promising ß-emitting Radionuclides, (67)Cu, (47)Sc and (161)Tb, with Emphasis on Doses Delivered to Minimal Residual Disease.

Authors:  Christophe Champion; Michele A Quinto; Clément Morgat; Paolo Zanotti-Fregonara; Elif Hindié
Journal:  Theranostics       Date:  2016-06-18       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.